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Abstract
Purpose Childhood paracetamol (acetaminophen) ingestion
with subsequent risk of hepatotoxicity is a major medical
problem. The aim of this study was to investigate the risk of
high-dose ingestion of orodispersible, fast-disintegrating
paracetamol tablets in children.
Methods A retrospective single-center case study of all
accidental selfadministrations of solid or orodispersible
500-mg paracetamol tablets occurring in children ≤6 years,
reported to the Swiss Toxicological Information Centre
between June 2003 and August 2009.
Results We found 187 cases with ingestion of solid 500-
mg paracetamol tablets and 16 cases with ingestion of
orodispersible 500-mg tablets. The mean ingested dose in
the orodispersible-tablet group was 59% higher than in the
solid-tablet group (p=0.085). Administration of activated
charcoal and/or N-acetylcysteine because of ingestion of a
potentially hepatotoxic paracetamol dose (≥150 mg/kg
body weight) was recommended in 32 patients (17.1%) in
the solid-tablet group and in five (31%) in the orodisper-
sible-tablet group.
Conclusions Orodispersible paracetamol formulations may
represent an important risk factor for severe paracetamol
poisoning in children. Over-the-counter availability may
contribute to increasing the use of this galenic formulation
and eventually the number of poisonings in children.
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Introduction
Childhood paracetamol (acetaminophen) ingestion with the
inherent risk of hepatotoxicity is a major medical problem
in most parts of the world. The issue of over-the-counter
medications leading to unintentional ingestions in children
and the importance of child-resistant closures for liquid
paracetamol preparations has already been addressed in
previous studies [1, 2]. At the beginning of 2002, an over-
the-counter orodispersible paracetamol formulation was
licensed in Switzerland. The aim of this study was to
investigate the risk of high-dose ingestion of orodispersible,
fast-disintegrating paracetamol tablets in children.
Methods
Data acquisition and inclusion criteria
The Swiss Toxicological Information Centre (STIC) col-
lects specific information from laypersons and detailed
clinical reports from physicians and hospitals about
poisoning cases by means of an in-house computer-based
and structured data recording and analysis system [3]. At
the time of the initial phonecall, clinical information is
obtained, such as the patient’s age and gender, circum-
stances of intoxication, ingested doses of all substances
involved, symptoms, and causality. These data are verified
and supplemented by information from discharge letters
and laboratory reports where available. We performed a
retrospective single-center analysis of all cases reported to
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our center of accidental self-administration of solid or
orodispersible 500-mg paracetamol tablets occurring in
children ≤6 years during the period June 2003 through
August 2009. Only cases with acute ingestion of a single
substance (paracetamol) and available information on the
ingested dose were included.
Statistical evaluation
Statistical analysis was performed with SPSS software
(Version 17.0; SPSS Inc., Chicago, IL, USA). Between-
group comparisons were made using the Mann–Whitney U
test (two-tailed).
Results
A search of our database yielded 187 pediatric cases with
ingestion of solid 500-mg paracetamol tablets (group 1) and
16 pediatric cases with ingestion of orodispersible 500-mg
tablets (group 2) which fulfilled the inclusion criteria. A
comparison of the two groups in terms of patient age,
number of ingested tablets, and ingested dose is shown in
Table 1. The mean ingested dose in the orodispersible-tablet
group was 59% higher than in the solid-tablet group,
although the difference did not reach statistical significance
(p=0.085). In nine patients (4.8%) in the solid-tablet group
and one (6.25%) in the orodispersible-tablet group, primary
gastrointestinal decontamination with orally administered
activated charcoal was recommended, because paracetamol
intake was between 150 and 200 mg/kg body weight. In 23
patients (12.3%) in the solid-tablet group and four (25%) in
the orodispersible-tablet group, hospitalization for N-
acetylcysteine (NAC) treatment was recommended because
paracetamol intake was ≥200 mg/kg body weight. Overall,
oral administration of activated charcoal and/or NAC
because of ingestion of a potentially hepatotoxic paracetamol
dose was recommended in 32 patients (17.1%) in the solid-
tablet group and in five (31%) in the orodispersible-tablet
group. Analysis of the clinical course of paracetamol-
poisoned children was not the focus of this study. However,
among the cases where such information was available, no
symptoms or signs of hepatotoxicity were observed after
appropriate treatment, and patients remained asymptomatic,
except for two among those hospitalized for NAC adminis-
tration who showed mild gastrointestinal symptoms such as
nausea and vomiting (one in the orodispersible-tablet group
and one in the solid-tablet group).
Discussion
Possible factors leading to ingestion of higher para-
cetamol doses with the orodispersible formulations are
rapid disintegration of the tablets within seconds of
contact with saliva, the pleasant feeling in the mouth, the
masked bitter paracetamol taste, and the candy-like
aspect, which may encourage consumption by children
[4]. Further factors not directly associated with the
orodispersible formulation, such as lack of child-resistant
closure and blister safety packaging, lack of vigilance by
parents and caregivers in the storage of medications, and
availability of adult-strength tablets, may have acted as
confounders that we were unable to control for in analyses
and which possibly contributed to increasing the risk of
high-dose paracetamol ingestion in the orodispersible-
formulation group.
Study limitations
The interpretation of our findings is limited by the
retrospective nature of the study design. In addition, data
from poison control centers are subject to reporting bias, as
we do not know the percentage of cases reported to the
STIC. Furthermore, the decision to only include patients
who ingested paracetamol alone led to small case numbers.
Conclusions
This study highlighted the problem of the availability of
orodispersible paracetamol formulations, which may repre-
sent an important risk factor for severe paracetamol
poisoning in children. Over-the-counter availability may
contribute to increasing the use of this galenic formulation
and eventually the number of poisonings in children.
Further studies with larger case numbers are required to
confirm our findings.
Table 1 Comparison of cases with solid versus orodispersible paracetamol tablets ingestion
Solid paracetamol n=187 Orodispersible paracetamol n=16 P value
Age (years): mean ± SD, (range), median 2.3±0.92 (0.8–6), 2 3±1.21 (1.5–5), 2.5 0.046
Number of ingested tablets: mean ± SD, (range), median 2.5±1.96 (0.3–8), 2 4.6±3.76 (1–14), 4 0.057
Ingested dose in mg/kg: mean ± SD, (range), median 98.7±77.7 (8.3–444), 71 157.3±147.6 (29.4–538), 100 0.085
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